Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 3/20 | 0.58 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.50 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.49 |
| ▸ | GNPAT | O15228 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | FAAH | O00519 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.47 |
| ▸ | GPR84 | Q9NQS5 | 6/20 | 0.47 |
| ▸ | PPARG | P37231 | 6/20 | 0.47 |
| ▸ | PPARD | Q03181 | 6/20 | 0.47 |
| ▸ | PPARA | Q07869 | 6/20 | 0.47 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.47 |
| ▸ | TSHR | P16473 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | TLR2 | O60603 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | FABP4 | P15090 | 2/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12673504 | 1.00 | NOD1 (0.58) | NOD1PLA2G2CPLA2G10GNPATMEN1 | |
| SCHEMBL15625141 | 1.00 | NOD1 (0.58) | NOD1PLA2G2CPLA2G10GNPATMEN1 | |
| SCHEMBL26453757 | 1.00 | NOD1 (0.58) | NOD1PLA2G2CPLA2G10GNPATMEN1 | |
| SCHEMBL15871528 | 1.00 | NOD1 (0.58) | NOD1PLA2G2CPLA2G10GNPATMEN1 | |
| SCHEMBL18250679 | 1.00 | NOD1 (0.58) | NOD1PLA2G2CPLA2G10GNPATMEN1 | |
| SCHEMBL14438871 | 1.00 | NOD1 (0.58) | NOD1PLA2G2CPLA2G10GNPATMEN1 | |
| SCHEMBL15680298 | 0.98 | NOD1 (0.56) | NOD1PLA2G2CPLA2G10GNPATMEN1 | |
| SCHEMBL13165224 | 0.93 | NOD1 (0.69) | NOD1PLA2G2CPLA2G10GNPATKMT2A | |
| SCHEMBL15341398 | 0.93 | NOD1 (0.69) | NOD1PLA2G2CPLA2G10GNPATKMT2A | |
| SCHEMBL15896458 | 0.93 | NOD1 (0.69) | NOD1PLA2G2CPLA2G10GNPATKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8815802-B2 | GLP-1 analogues and derivatives | NOVO NORDISK A/S (DK) | 2014-08-26 | — | — | US | disclosed |
| US-8815802-B2 | GLP-1 analogues and derivatives | NOVO NORDISK A/S (DK) | 2014-08-26 | — | — | US | disclosed |
| US-20130053311-A1 | GLP-1 ANALOGUES AND DERIVATIVES | NOVO NORDISK A/S (DK) | 2013-02-28 | — | — | US | disclosed |
| US-20130053311-A1 | GLP-1 ANALOGUES AND DERIVATIVES | NOVO NORDISK A/S (DK) | 2013-02-28 | — | — | US | disclosed |
| US-8129343-B2 | Acylated GLP-1 compounds | NOVO NORDISK A/S (DK) | 2012-03-06 | — | — | US | disclosed |
| US-8129343-B2 | Acylated GLP-1 compounds | NOVO NORDISK A/S (DK) | 2012-03-06 | — | — | US | disclosed |
| US-20100222269-A1 | IMPROVED DERIVATIVES OF AMYLIN | NOVO NORDISK A/S (DK) | 2010-09-02 | — | — | US | disclosed |
| US-20100222269-A1 | IMPROVED DERIVATIVES OF AMYLIN | NOVO NORDISK A/S (DK) | 2010-09-02 | — | — | US | disclosed |
| US-20090156478-A1 | Acylated GLP-1 Compounds | NOVO NORDISK A/S (DK) | 2009-06-18 | — | — | US | disclosed |
| US-20090156478-A1 | Acylated GLP-1 Compounds | NOVO NORDISK A/S (DK) | 2009-06-18 | — | — | US | disclosed |
| US-20080207507-A1 | Extended Glp-1 Compounds | NOVO NORDISK A/S (DK) | 2008-08-28 | — | — | US | disclosed |
| US-20080207507-A1 | Extended Glp-1 Compounds | NOVO NORDISK A/S (DK) | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207507-A1 | Extended Glp-1 Compounds | GLP1R, GIPR, IAPP | NOD1 933/4885PLA2G2C 1068/4885PLA2G10 935/4885 |
| US-20100222269-A1 | IMPROVED DERIVATIVES OF AMYLIN | IAPP, GLP1R, ALB | NOD1 281/4885PLA2G2C 1314/4885PLA2G10 2112/4885 |
| US-20090156478-A1 | Acylated GLP-1 Compounds | GLP1R, GIPR, GCGR | NOD1 1340/4885PLA2G2C 741/4885PLA2G10 604/4885 |
| US-20130053311-A1 | GLP-1 ANALOGUES AND DERIVATIVES | GLP1R, IAPP, SLC5A1 | NOD1 221/4885PLA2G2C 1816/4885PLA2G10 4084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.